Trial Profile
Safety surveillance study of influenza virus vaccine live intranasal (Fluenz) in children in England during early 2016 influenza season
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Sep 2017
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine live (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors AstraZeneca
- 19 Sep 2017 Design keyword (prospective), subject gender (male and female) and actual patient number are assumed.
- 19 Sep 2017 New trial record
- 30 Aug 2017 Results presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management